Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update

Area of Science:

• Hepatology
• Pharmacology
• Metabolic Diseases

Background:

• Nonalcoholic steatohepatitis (NASH) is a significant global health concern, closely linked to the obesity pandemic.
• Current research focuses on developing novel pharmacotherapies to address NASH's complex pathological pathways.

Purpose of the Study:

• To review therapeutic agents for NASH evaluated in Phase 2 and 3 randomized trials.
• To discuss novel drug targets and combination therapy strategies for NASH treatment.

Main Methods:

• Review of published Phase 2 and 3 randomized clinical trials for NASH pharmacotherapies.
• Analysis of therapeutic agents targeting metabolic, inflammatory, liver-gut axis, and fibrotic pathways.
• Discussion of drugs targeting nuclear receptors, chemokine receptors, lipid metabolism, and GLP-1 receptors.

Main Results:

• Several novel therapeutic agents targeting diverse NASH pathways have advanced to late-stage clinical trials.
• Combination therapies are being explored to enhance treatment efficacy.
• Lessons from unsuccessful trials provide critical insights for future drug development.

Conclusions:

• Active research is yielding promising pharmacotherapies for NASH, addressing multiple disease mechanisms.
• Understanding trial outcomes, both positive and negative, is crucial for advancing NASH treatment.
• Targeting metabolic, inflammatory, and fibrotic pathways offers a multifaceted approach to managing NASH.